

3rd Meeting of the European Research Initiative on ALCL



Punting on the River Cam with the chapel of King's College in the background

July 3rd-4th 2012
Kings College, University of Cambridge,
UK

<http://www.erialcl.net/>

Organisers: Dr Suzanne Turner, Dr Olaf Merkel and Dr Lukas Kenner

„Welcome to Cambridge“

European Research Initiative on ALCL

The European Research Initiative on ALCL (ERIA) was conceived at the American Association for Cancer Research 100th Annual Meeting in Denver, CO, USA back in 2009 when Suzanne Turner, Olaf Merkel and Lukas Kenner met at a poster. Our aim is to strengthen cooperation and partnership of European research groups focused on this disease in order to accelerate scientific progress. With this aim in mind we anticipate that more efficacious and less toxic therapeutic strategies will be developed for the treatment of those patients diagnosed with ALCL.

VENUE

King's College was founded in 1441 by Henry VI (1421-71) and is one of the 31 colleges in the University of Cambridge. King's has an outstanding academic record and is also world-famous for its Chapel and choir. The Christmas Eve service from King's (*A Festival of Nine Lessons and Carols*) is broadcast to millions around the world.

SCIENTIFIC PROGRAM

Tuesday, 3rd July

11:30 Arrival and coffee

12:00 Introductory remarks

Plenary Talk

12:05 Mariusz Wasik, University of Pennsylvania, USA – Diverse mechanisms of ALK-mediated oncogenesis; potential therapeutic implications

1:00 Buffet Lunch

Session 1

Chair: Suzanne Turner

14:00 Melanie Hassler, University of Vienna, Austria - Essential role for DNA methylation and DNMT1 in NPM-ALK mediated Lymphomagenesis

14:30 Naushad Moti, University of Cambridge, UK – Anaplastic Large Cell Lymphoma stem cells possess a gene expression profile reflective of an early thymic progenitor pointing to a primitive cell of origin

Coffee

15:00 George Rassidakis, University of Athens, Greece – The JunB/CD30 axis contributes to cell cycle deregulation in ALK+ Anaplastic Large Cell Lymphoma.

15:30 Olaf Merkel, SALK Institute, Salzberg, Austria – miRNAs in nodal T-cell lymphomas

16:00 Stephan Mathas, Charite, Berlin, Germany - genome wide analysis of DNaseI hypersensitivity sites and transcription factor mapping in Hodgkin lymphoma

17:00 Chauffeured tour of the Cambridge colleges by punt

19:00 Drinks Reception

19:30 Dinner

Wednesday, 4th July

8:00 Breakfast in the hall

Session 2: Future therapies

Chair: Olaf Merkel

9:00 Mark Dawson, University of Cambridge, UK – MLL and epigenetics

9:30 Dana Kennedy, Seattle Genetics, WA, USA - Brentuximab vedotin and the evolution of targeting CD30 in systemic ALCL

10:00 Carlo Gambacorti-Passerini, University of Milano Bicocca, Italy - Crizotinib obtains durable responses in advanced chemoresistant ALK+ lymphoma patients. Analysis of prognostic variables.

10:30 Coffee

11:00 Amos Burke / Denise Williams, Addenbrooke's Hospital, Cambridge, UK – Paediatric lymphoma clinical trials in Europe

Session 3: Mechanisms of Lymphomagenesis

Chair: Lukas Kenner

11:30 Roberto Chiarle, University of Turin, Italy – ALK mediated oncogenic stress

12:00 Ming-Qing Du, Department of Pathology, University of Cambridge, UK – The role of NFκB in lymphoma development

12:30 Irina Bonzheim, University of Tuebingen, Germany - DDX21, a central gene for rRNA Biogenesis is differentially expressed in ALK+ ALCL, and is important for proliferation and survival of ALK+ ALCL cells

13:00 Buffet Lunch

13:30 Discussion and close of meeting

Venue of 2013 meeting

European funding opportunities

15:00 Afternoon social event – drinks in The Eagle (the pub made famous by Watson and Crick)

Organizing committee:

Suzanne Turner, Cambridge; Lukas Kenner, Vienna; Olaf Merkel, Salzburg

Participants

Suzanne Turner, Cambridge, UK, sdt36@cam.ac.uk
Lukas Kenner, Vienna, Austria, Lukas.kenner@meduniwien.ac.at
Olaf Merkel, Salzburg, Austria, o.merkel@salk.at
Mariusz Wasik, PA, USA, wasik@mail.med.upenn.edu
Ming-Qing Du, Cambridge, UK, mqd20@cam.ac.uk
Mike Omakobia, Cambridge, UK, mo365@cam.ac.uk
Gavin Garland, Cambridge, UK, gdg26@cam.ac.uk
Tim Malcolm, Cambridge, UK, timm2@cam.ac.uk
Naushad Moti, Cambridge, UK, nm422@cam.ac.uk
Mark Dawson, Cambridge, UK, mafd2@cam.ac.uk
Falko Fend, Tuebingen, Germany, falko.fend@med.uni-tuebingen.de
Leticia Quinatanilla-Fend, Tuebingen, Germany, leticia.quinatanilla-fend@med.uni-tuebingen.de
Irina Bonzheim, Tuebingen, Germany, irina.bonzheim@med.uni-tuebingen.de
Julia Steinhilber, Tuebingen, Germany, julie.steinhilber@med.uni-tuebingen.de
Janine Schmidt, Tuebingen, Germany, janine.schmidt@med.uni-tuebingen.de
Frank Hamacher, Salzburg, Austria, f.hamacher@salk.at
Eveline Sift, Salzburg, Austria, e.sift@salk.at
Dana Kennedy, Seattle Genetics, dkennedy@seagen.com
George Rassidakis, Athens, Greece, grassidakis@hotmail.com
Roberto Chiarle, Turin, Italy, roberto.chiarle@unito.it
Kamel Ait-Tahar, Riyadh, Saudi Arabia, akemal80@hotmail.com
Shahid Mian, Ha'il, Saudi Arabia, sa.mian@uoh.edu.sa
Carlo Gambacorti-Passarini, Monza, Italy, carlo.gambacorti@unimib.it
Amos Burke, Cambridge, UK, amos.burke@addenbrookes.nhs.uk
Denise Williams, Cambridge, UK, denise.williams@addenbrookes.nhs.uk
Melanie Hassler, University of Vienna, Austria, melanie.hassler@meduniwien.ac.at
Stephan Mathas, Charite, University of Berlin, Germany, Stephan.mathas@charite.de

Apologies

Karen Pulford, Oxford
Emanuela Colombo, Milan
Fabienne Magetto, Toulouse
Sylvie Giuriato, Toulouse
Estelle Espinos, Toulouse

Sponsorship

We are grateful to Leukaemia and Lymphoma Research (LLR) and the British Association for Cancer Research (BACR) for their generous support.

